|
Name |
Epicoccarine B
|
Molecular Formula | C23H31NO5 | |
IUPAC Name* |
(3E,5S)-5-[(S)-hydroxy-(4-hydroxyphenyl)methyl]-3-[(E,2S,4R)-1-hydroxy-2,4,6-trimethylnon-6-enylidene]pyrrolidine-2,4-dione
|
|
SMILES |
CC/C=C(\C)/C[C@H](C)C[C@H](C)/C(=C\1/C(=O)[C@@H](NC1=O)[C@H](C2=CC=C(C=C2)O)O)/O
|
|
InChI |
InChI=1S/C23H31NO5/c1-5-6-13(2)11-14(3)12-15(4)20(26)18-22(28)19(24-23(18)29)21(27)16-7-9-17(25)10-8-16/h6-10,14-15,19,21,25-27H,5,11-12H2,1-4H3,(H,24,29)/b13-6+,20-18+/t14-,15-,19-,21-/m0/s1
|
|
InChIKey |
CRZCNQJDEBVYEU-DEWQWJSZSA-N
|
|
Synonyms |
Epicoccarine B
|
|
CAS | NA | |
PubChem CID | 102325298 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 401.5 | ALogp: | 4.4 |
HBD: | 4 | HBA: | 5 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 107.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 29 | QED Weighted: | 0.223 |
Caco-2 Permeability: | -4.959 | MDCK Permeability: | 0.00000712 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.067 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.03 |
30% Bioavailability (F30%): | 0.001 |
Blood-Brain-Barrier Penetration (BBB): | 0.038 | Plasma Protein Binding (PPB): | 99.59% |
Volume Distribution (VD): | 0.165 | Fu: | 0.79% |
CYP1A2-inhibitor: | 0.285 | CYP1A2-substrate: | 0.657 |
CYP2C19-inhibitor: | 0.413 | CYP2C19-substrate: | 0.147 |
CYP2C9-inhibitor: | 0.9 | CYP2C9-substrate: | 0.958 |
CYP2D6-inhibitor: | 0.942 | CYP2D6-substrate: | 0.513 |
CYP3A4-inhibitor: | 0.52 | CYP3A4-substrate: | 0.521 |
Clearance (CL): | 2.879 | Half-life (T1/2): | 0.486 |
hERG Blockers: | 0.025 | Human Hepatotoxicity (H-HT): | 0.195 |
Drug-inuced Liver Injury (DILI): | 0.933 | AMES Toxicity: | 0.004 |
Rat Oral Acute Toxicity: | 0.388 | Maximum Recommended Daily Dose: | 0.844 |
Skin Sensitization: | 0.18 | Carcinogencity: | 0.044 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.049 |
Respiratory Toxicity: | 0.646 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC006123 | 0.337 | D0Z1WA | 0.286 | ||||
ENC005246 | 0.327 | D0X9ZC | 0.281 | ||||
ENC002604 | 0.327 | D00LFB | 0.280 | ||||
ENC003476 | 0.302 | D0YX4S | 0.277 | ||||
ENC003004 | 0.302 | D0F6EO | 0.272 | ||||
ENC004958 | 0.302 | D0R1QE | 0.269 | ||||
ENC004092 | 0.296 | D0JE2E | 0.267 | ||||
ENC005814 | 0.294 | D03CEF | 0.267 | ||||
ENC005813 | 0.294 | D0Q9ON | 0.265 | ||||
ENC001493 | 0.286 | D03KIA | 0.265 |